Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

@article{Galsky2011TreatmentOP,
  title={Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.},
  author={M. Galsky and N. Hahn and J. Rosenberg and G. Sonpavde and T. Hutson and W. Oh and R. Dreicer and N. Vogelzang and C. Sternberg and D. Bajorin and J. Bellmunt},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 17},
  pages={
          2432-8
        }
}
  • M. Galsky, N. Hahn, +8 authors J. Bellmunt
  • Published 2011
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • PURPOSE Cisplatin-based combination chemotherapy is considered standard first-line treatment for patients with metastatic urothelial carcinoma. However, a large proportion of patients with metastatic urothelial carcinoma are considered "unfit" for cisplatin. The purpose of this review is to define unfit patients and to identify treatment options for this subgroup of patients. PATIENTS AND METHODS In this review, the criteria used to define unfit patients are explored and the results of… CONTINUE READING
    View PDF
    283 Citations
    Highly Influential Citations
    3
    Background Citations
    92
    Methods Citations
    12
    Results Citations
    4

    Paper Mentions

    Interventional Clinical Trial
    hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"
    Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2… Expand
    ConditionsBladder Carcinoma
    InterventionDrug
    Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    April 2019 - February 2023
    Interventional Clinical Trial
    Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma
    Phase II Multicentre, randomized, open-label study to evaluate the safety and efficacy of avelumab with gemcitabine/carboplatin versus gemcitabine/carboplatin alone in patients with… Expand
    ConditionsMetastatic Urothelial Cancer
    InterventionCombination Product
    Associació per a la Recerca Oncologica, Spain
    May 2018 - April 2020
    283 Citations
    Citation Type

    Citation Type

    [Urothelial cancer: update on systemic treatment options].
    Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community.
    • 37
    Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer
    • 4
    Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens.
    Cisplatin Ineligibility for Patients With Metastatic Urothelial Carcinoma: A Survey of Clinical Practice Perspectives Among US Oncologists
    • 1
    • PDF
    Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer.
    • 22
    Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?
    • 37
    Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer.
    • 27
    Defining cisplatin eligibility in patients with muscle-invasive bladder cancer
    Evolving Treatment of Advanced Urothelial Cancer.
    • S. Sridhar
    • Medicine
    • Journal of oncology practice
    • 2017
    • 13

    References

    SHOWING 1-10 OF 72 REFERENCES
    Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.
    • 44
    Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.
    • M. Galsky, G. Chen, +6 authors G. Sonpavde
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2011
    • 56
    • PDF
    A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.
    • 163
    Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.
    • 102
    Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.
    • 106
    Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.
    • M. Galsky, G. Chen, +6 authors G. Sonpavde
    • Medicine
    • Annals of oncology : official journal of the European Society for Medical Oncology
    • 2012
    • 89
    Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience
    • 11
    Single-Agent Gemcitabine in Previously Untreated Elderly Patients with Advanced Bladder Carcinoma: Response to Treatment and Correlation with the Comprehensive Geriatric
    • 47
    Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy.
    • 26
    Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial.
    • 133